Patents by Inventor Annamari Heiskanen
Annamari Heiskanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10513724Abstract: The present disclosure relates to compositions and methods useful for the production of recombinant glycoproteins in filamentous fungal cells, such as Trichoderma cells, wherein at least 90% (mol %), preferably at least 95% of the total neutral N-glycans of said produced recombinant glycoprotein are mammalian-like N-glycans. More specifically, the invention provides a filamentous fungal cell comprising i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s); ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase; iii. a recombinant polynucleotide for increasing ?1, 2 mannosidase activity;and, iv. a recombinant polynucleotide encoding said heterologous glycoprotein.Type: GrantFiled: July 21, 2015Date of Patent: December 24, 2019Assignee: GLYKOS FINLAND OYInventors: Jari Natunen, Anne Leppänen, Heidi Salminen, Jukka Hiltunen, Anne Kanerva, Annamari Heiskanen, Ann Westerholm-Parvinen, Georg Schmidt, Anne Huuskonen, Eero Mustalahti, Christopher Landowski, Markku Saloheimo, Juhani Saarinen, Benjamin Patrick Sommer, Ramon Wahl, Christian Ostermeier, Bernhard Helk
-
Patent number: 10000734Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: May 23, 2016Date of Patent: June 19, 2018Assignee: GLYKOS FINLAND OYInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20170159094Abstract: The present disclosure relates to compositions and methods useful for the production of recombinant glycoproteins in filamentous fungal cells, such as Trichoderma cells, wherein at least 90% (mol %), preferably at least 95% of the total neutral N-glycans of said produced recombinant glycoprotein are mammalian-like N-glycans. More specifically, the invention provides a filamentous fungal cell comprising i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s); ii.a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase; iii. a recombinant polynucleotide for increasing ?1, 2 mannosidase activity;and, iv. a recombinant polynucleotide encoding said heterologous glycoprotein.Type: ApplicationFiled: July 21, 2015Publication date: June 8, 2017Applicant: GLYKOS FINLAND OYInventors: Jari Natunen, Anne Leppänen, Heidi Salminen, Jukka Hiltunen, Anne Kanerva, Annamari Heiskanen, Ann Westerholm-Parvinen, Georg Schmidt, Anne Huuskonen, Eero Mustalahti, Christopher Landowski, Markku Saloheimo, Juhani Saarinen, Benjamin Patrick Sommer, Ramon Wahl, Christian Ostermeier, Bernhard Helk
-
Publication number: 20170002095Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.Type: ApplicationFiled: September 14, 2016Publication date: January 5, 2017Applicant: Glykos Finland OyInventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
-
Publication number: 20160333309Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: May 23, 2016Publication date: November 17, 2016Applicant: Glykos Finland OyInventors: Jarmo LAINE, Taina JAATINEN, Heidi ANDERSON, Johanna NYSTEDT, Sari TIITINEN, Anita LAITINEN, Ulla IMPOLA, Tero Satomaa, Jari NATUNEN, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Carbohydrate profile compositions from human cells and methods for analysis and modification thereof
Patent number: 9410126Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.Type: GrantFiled: March 6, 2014Date of Patent: August 9, 2016Assignee: GLYKOS FINLAND OYInventors: Tero Satomaa, Jari Natunen, Jarmo Laine, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen, Taina Jaatinen, Ulla Impola, Milla Mikkola, Heidi Anderson -
Patent number: 9382512Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: January 17, 2012Date of Patent: July 5, 2016Assignee: GLYKOS FINLAND OYInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20150140576Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.Type: ApplicationFiled: October 24, 2014Publication date: May 21, 2015Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
-
Publication number: 20150072419Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.Type: ApplicationFiled: March 6, 2014Publication date: March 12, 2015Inventors: Tero SATOMAA, Jari NATUNEN, Jarmo LAINE, Annamari HEISKANEN, Maria BLOMQVIST, Anne OLONEN, Juhani SAARINEN, Taina JAATINEN, Ulla IMPOLA, Milla MIKKOLA, Heidi ANDERSON
-
Publication number: 20140248697Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: April 14, 2014Publication date: September 4, 2014Applicant: GLYKOS FINLAND OYInventors: Jarmo LAINE, Taina JAATINEN, Heidi ANDERSON, Johanna NYSTEDT, Sari TIITINEN, Anita LAITINEN, Ulla IMPOLA, Tero Satomaa, Jari NATUNEN, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20140234318Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.Type: ApplicationFiled: March 24, 2014Publication date: August 21, 2014Applicant: GLYKOS FINLAND OYInventors: Jari NATUNEN, Susann TENEBERG, Karl-Anders KARLSSON, Tero SATOMAA, Annamari HEISKANEN
-
Patent number: 8759005Abstract: The present invention reveals novel methods for producing novel carbohydrate compositions, glycomes, from animal tissues. The tissue substrate materials can be total tissue samples and fractionated tissue parts, or artificial models of tissues such as cultivated cell lines. The invention is further directed to the compositions and compositions produced by the methods according to the invention. The invention further represent methods for analysis of the glycomes, especially mass spectrometric methods.Type: GrantFiled: July 11, 2006Date of Patent: June 24, 2014Assignee: Glykos Finland OyInventors: Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen
-
Carbohydrate profile compositions from human cells and methods for analysis and modification thereof
Patent number: 8691774Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.Type: GrantFiled: July 11, 2006Date of Patent: April 8, 2014Assignee: Glykos Finland OyInventors: Tero Satomaa, Jari Natunen, Jarmo Laine, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen, Taina Jaatinen, Ulla Impola, Milla Mikkola, Heidi Anderson -
Patent number: 8236487Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.Type: GrantFiled: August 20, 2002Date of Patent: August 7, 2012Assignee: Glykos Finland OyInventors: Jari Natunen, Susann Teneberg, Karl-Anders Karlsson, Tero Satomaa, Annamari Heiskanen
-
Publication number: 20120190058Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: January 17, 2012Publication date: July 26, 2012Applicants: Glykos Finland Oy, SUOMEN PUNAINEN RISTI, VERIPALVELUInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Patent number: 8110366Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: July 7, 2006Date of Patent: February 7, 2012Assignees: Suomen Punainen Risti, Veripalvelu, Glykos Finland OyInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sarl Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20100145032Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.Type: ApplicationFiled: January 18, 2008Publication date: June 10, 2010Applicants: Suomen Punainen Risti, Veripalelu, Glykos Finland Ltd.Inventors: Jarmo Laine, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinin, Sari Tiitinen, Ulla Impola, Milla Mikkola, Hanna Salo, Olli Aitio, Leena Valmu, Suvi Natunen, Heidi Anderson, Virve Pitkänen, Jukka Partanen, Taina Jaatinen, Minna Tiitanen, Tia Hirvonen
-
Publication number: 20100068806Abstract: The present invention provides methods and materials to modulate and grow stem cells by contacting stem cells with a binder recognizing terminal glycan structures of stem cells. The modulation can be morphological change, change in differentiation status, biological status or adherence. The materials provided in the present invention are also useful to screen such a binding agents and binders.Type: ApplicationFiled: January 18, 2008Publication date: March 18, 2010Applicants: SUOMEN PUNAINEN RISTI, VERIPALVELU, Glykos Finland Ltd.Inventors: Jarmo Laine, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen, Sari Tiitiene, Ulla Impola, Milla Mikkola, Leena Valmu, Minna Tiittanen
-
Publication number: 20100055710Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.Type: ApplicationFiled: July 11, 2006Publication date: March 4, 2010Applicants: SUOMEN PUNAINEN RISTI, VERIPALVELU, GLYKOS FINLAND OYInventors: Tero Satomaa, Jari Natunen, Jarmo Laine, Annamari Heiskanen, Maria Blomqvist, Anne Olonen, Juhani Saarinen, Taina Jaatinen, Ulla Impola, Milla Mikkola, Heidi Anderson
-
Publication number: 20100047892Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by changing sialylation and/or fucosylation levels of the cells. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. The control methods are preferably mass spectrometric methods.Type: ApplicationFiled: January 18, 2008Publication date: February 25, 2010Applicants: SUOMEN PUNAINEN RISTI,VERIPALVELU, Glykos Finland Ltd.Inventors: Jarmo Laine, Tero Satomaa, Jari Natunen, Taina Jaatinen, Annamari Heiskanen, Johanna Nystedt